Omeros Target of Unusually High Options Trading (NASDAQ:OMER)

Omeros Co. (NASDAQ:OMER) was the target of some unusual options trading on Tuesday. Stock traders acquired 1,215 put options on the stock. This represents an increase of approximately 1,458% compared to the average volume of 78 put options.

A number of equities analysts recently commented on OMER shares. Wedbush set a $19.00 price objective on Symantec and gave the stock a “hold” rating in a research report on Monday. Zacks Investment Research downgraded H&E Equipment Services from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine cut Yirendai from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 26th. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $71.00 target price on shares of ExlService in a research note on Monday, May 6th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Omeros presently has a consensus rating of “Hold” and a consensus price target of $25.80.

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Advisory Services Network LLC acquired a new stake in shares of Omeros in the 1st quarter worth approximately $69,000. Legal & General Group Plc lifted its stake in Omeros by 12.7% in the 4th quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 945 shares in the last quarter. National Asset Management Inc. lifted its stake in Omeros by 19.7% in the 4th quarter. National Asset Management Inc. now owns 15,180 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 2,500 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of Omeros by 16,167.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 9,862 shares during the period. Finally, Metropolitan Life Insurance Co. NY lifted its stake in shares of Omeros by 417.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,004 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 12,911 shares during the period. Institutional investors and hedge funds own 52.12% of the company’s stock.

Shares of Omeros stock traded up $0.04 on Thursday, hitting $15.49. The stock had a trading volume of 214,703 shares, compared to its average volume of 524,451. The business has a 50 day moving average price of $16.23. The firm has a market cap of $756.51 million, a PE ratio of -6.98 and a beta of 3.04. Omeros has a 52-week low of $10.30 and a 52-week high of $27.00.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.04). The business had revenue of $21.80 million during the quarter, compared to analysts’ expectations of $23.18 million. The firm’s revenue was up 1271.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.62) earnings per share. On average, sell-side analysts forecast that Omeros will post -1.68 EPS for the current fiscal year.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Understanding Market Liquidity

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.